2020
Calliditas was listed on the Nasdaq Global Select Market, raising approximately USD 96,890,000
Calliditas acquired a controlling interest in Genkyotex SA
Calliditas announced positive topline results from the pivotal Phase 3 NefIgArd trial
2019
The pivotal Phase 3 clinical trial NefIgArd Part A was fully recruited
Calliditas and Everest Medicines entered into a license agreement to develop and commercialize Calliditas’ leading product candidate in Greater China and Singapore.
Calliditas exclusively in-licensed Budenofalk 3 mg oral capsules for the US market from the German pharmaceutical company, Dr. Falk Pharma GmbH.
Calliditas establishes a US presence
2018
The first patient was enrolled in the pivotal clinical Phase 3 study NefIgArd
Calliditas was listed on Nasdaq Stockholm’s main list, raising approximately SEK 739 million
2017
Pharmalink changed its name to Calliditas Therapeutics
The Phase 2b NEFIGAN study results were published in The Lancet
The company had end-of-Phase 2 meetings with the FDA and EMA
2016
The company prepared for end-of-Phase 2 meetings with the FDA and EMA
Pharmalink obtained orphan drug designation from the EMA for lead product candidate in Europe
A meta-analysis was published by the Tufts Medical Center
2015
Pharmalink was invited to work with the Kidney Health Initiative (American Society of Nephrology) to identify surrogate endpoints in IgA nephropathy
The company received financing from existing investors to progress the clinical process towards Phase 3
Pharmalink announced positive initial results from the Phase 2b NEFIGAN trial, which achieved its primary endpoint in a planned interim analysis
2014
Core patents for lead product candidate were granted in the US, Europe, China and Hong Kong
2013
Investinor joined existing investors to finance the completion of the Phase 2b study
2012
Owners, including Industrifonden and Bengt Julander, financed the launch of the pivotal Phase 2b NEFIGAN trial
2011
Pharmalink gained exclusive rights to the formulation technology, TARGIT®, for developing and manufacturing lead product candidate under a 2011 agreement with Archimedes Development Ltd
2010
Pharmalink obtained orphan drug designation from the FDA for lead product candidate in the United States
2009
The Phase 2a study with lead product candidate was completed with positive results
2008
Identified the company’s lead product candidate
2004
Calliditas was founded as a public limited company under the laws of Sweden on February 20, 2004 under the name Pharmalink AB and was registered with the Swedish Companies Registration Office on April 15, 2004.